Document is current
Any future updates will be listed below
-
Authors
Tolcher, Anthony W https://orcid.org/0000-0002-6322-9721
Gordon, Michael
Mahoney, Kathleen M https://orcid.org/0000-0002-3869-6803
Seto, Anna
Zavodovskaya, Marianna
Hsueh, Chia-Hsiang
Zhai, Shuyan
Tarnowski, Thomas
Jürgensmeier, Juliane M
Stinson, Susanna
Othman, Ahmed A
Chen, Tianling
Strauss, James
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03954704 at ClinicalTrials.govnct03954704 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005267
377 Characterization of peripheral biomarkers of GS-1423, a first in class bifunctional anti-CD73-TGFβ receptor II- trap molecule, in a phase 1 dose escalation study in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.377
Documents that mention this clinical trial
Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005267
377 Characterization of peripheral biomarkers of GS-1423, a first in class bifunctional anti-CD73-TGFβ receptor II- trap molecule, in a phase 1 dose escalation study in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.377
-
Funding
Funding for this research was provided by:
Gilead Sciences (N/A)
- License Information
